BR0307342A - Terapia de combinação de antagonista aldosterona e agente antiiflamatório não-esteróide para prevenir ou tratar distúrbios cardiovasculares - Google Patents

Terapia de combinação de antagonista aldosterona e agente antiiflamatório não-esteróide para prevenir ou tratar distúrbios cardiovasculares

Info

Publication number
BR0307342A
BR0307342A BR0307342-4A BR0307342A BR0307342A BR 0307342 A BR0307342 A BR 0307342A BR 0307342 A BR0307342 A BR 0307342A BR 0307342 A BR0307342 A BR 0307342A
Authority
BR
Brazil
Prior art keywords
prevent
combination therapy
cardiovascular disorders
treat cardiovascular
steroidal anti
Prior art date
Application number
BR0307342-4A
Other languages
English (en)
Inventor
Ellen G Mcmahon
Ricardo Rocha
Amy E Rudolph
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0307342A publication Critical patent/BR0307342A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TERAPIA DE COMBINAçãO DE ANTAGONISTA ALDOSTERONA E AGENTE ANTIINFLAMATóRIO NãO-ESTERóIDE PARA PREVENIR OU TRATAR DISTúRBIOS CARDIOVASCULARES". São descritas combinações de bloqueadores de aldosterona e NSAIDs úteis no tratamento de inflamação.
BR0307342-4A 2002-01-30 2003-01-30 Terapia de combinação de antagonista aldosterona e agente antiiflamatório não-esteróide para prevenir ou tratar distúrbios cardiovasculares BR0307342A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35300802P 2002-01-30 2002-01-30
PCT/US2003/002923 WO2003063908A1 (en) 2002-01-30 2003-01-30 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders

Publications (1)

Publication Number Publication Date
BR0307342A true BR0307342A (pt) 2004-12-21

Family

ID=27663163

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307342-4A BR0307342A (pt) 2002-01-30 2003-01-30 Terapia de combinação de antagonista aldosterona e agente antiiflamatório não-esteróide para prevenir ou tratar distúrbios cardiovasculares

Country Status (10)

Country Link
EP (1) EP1469884A1 (pt)
JP (1) JP2005521665A (pt)
KR (1) KR20040078683A (pt)
CN (1) CN1625412A (pt)
BR (1) BR0307342A (pt)
CA (1) CA2473797A1 (pt)
MX (1) MXPA04007128A (pt)
PL (1) PL371436A1 (pt)
WO (1) WO2003063908A1 (pt)
ZA (1) ZA200405829B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029068A1 (en) * 2002-09-25 2004-04-08 Forbes Medi-Tech Inc. Derivatives comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
US8258181B2 (en) 2005-03-23 2012-09-04 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
WO2014160702A1 (en) 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550124A (en) * 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
JPH10500669A (ja) * 1994-04-12 1998-01-20 アルザ・コーポレーション サイトカイン阻害薬に関するスクリーニング法
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AU5687199A (en) * 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
WO2002009759A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders

Also Published As

Publication number Publication date
EP1469884A1 (en) 2004-10-27
CN1625412A (zh) 2005-06-08
JP2005521665A (ja) 2005-07-21
MXPA04007128A (es) 2005-03-31
CA2473797A1 (en) 2003-08-07
WO2003063908A1 (en) 2003-08-07
PL371436A1 (en) 2005-06-13
KR20040078683A (ko) 2004-09-10
ZA200405829B (en) 2005-10-21

Similar Documents

Publication Publication Date Title
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
NO20044054L (no) Administrering av midler for behandling av betennelse
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
AR025964A1 (es) Tratamiento nasal topico
CY1105429T1 (el) Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
TR200002625T2 (tr) Vitronektin Reseptörü Antagonistleri
DE60229235D1 (de) D kupfersulfaten und sucralphat
ATE249242T1 (de) Kombinationstherapie von angiotensin- konvertierendem enzym hemmer und epoxy- steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
BR0307342A (pt) Terapia de combinação de antagonista aldosterona e agente antiiflamatório não-esteróide para prevenir ou tratar distúrbios cardiovasculares
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
BR0009289A (pt) Uso de inibidores da vasopeptidase para tratar angina pectoris
FR2797399B1 (fr) Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
WO2004062598A3 (en) Anti-inflammatory and anti-thrombotic compounds and their compositions
WO1999045905A3 (en) Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
TR200402015T4 (tr) Ağız boşluğuna lokal uygulama için NSAID içeren susuz jel

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.